Oasmia Pharmaceutical AB
DelistedCIK 1607245fmd_0K7BS9M0JY13FGN8V74DREGCTQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: May 01, 2015 to Apr 30, 2018, 3 periods
| Line item | FY2016 | FY2017 | FY2018 |
|---|---|---|---|
| Total revenues | 6 | 0 | 3 |
| Research and development | 114 | 98 | 66 |
| Operating income | (133) | (140) | (104) |
| Interest expense | 10 | 20 | 14 |
| Income before taxes | (142) | (160) | (118) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (156) | (158) | (132) |
| Net income | (142) | (160) | (118) |